This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 8, 2012 /PRNewswire/ --
Life Technologies Corporation (NASDAQ:LIFE) today announced publication in the Journal of the American Medical Association
1 (JAMA) of a study that underscores the clinical utility of the company's early stage lung cancer test, Pervenio™ Lung RS. Launched in
September 2012, the genetic test has now been demonstrated to reliably identify patients who are at high risk for mortality following surgery even for the earliest stage of lung cancer.
The test was initially validated through two independent, blinded retrospective studies involving approximately 1,500 patients, which were published in the
March 2012 issue of The Lancet.
2 The new study reports data from a subset of patients included in the larger validation studies. Specifically, it looks at those patients with "T1a, node-negative" tumors, cancers that are smaller than two centimeters in diameter and that have no detectable spread of the disease.
"We know that roughly a quarter of patients with T1a, node negative tumors will die within five years, most often with recurrent lung cancer," said
Michael Mann, M.D., senior author of the study. "And yet these patients do not receive any chemotherapy following surgery because there are no guidelines for identifying which T1a patients are at high risk for mortality."
Dr. Mann is associate professor of cardiothoracic surgery at the
University of California, San Francisco and was involved in the development of the Pervenio
TM Lung RS test along with co-author
David Jablons, M.D., chief of general thoracic surgery at the
University of California, San Francisco.
"By the time the disease recurrence can be detected, it is too late for therapies to be curative," said Dr. Jablons. "We know from previous clinical trials that chemotherapy can cure metastatic lung cancer when it is treated even before it can be detected. Therefore, we need to identify the high-risk patients earlier, immediately after surgery if possible. Current published guidelines already recommend consideration of chemotherapy at that time even for stage I patients who are believed to be at the highest risk."